These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 3825747

  • 1. Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice.
    Popovic S, Bartlett RR.
    Agents Actions; 1986 Dec; 19(5-6):313-4. PubMed ID: 3825747
    [No Abstract] [Full Text] [Related]

  • 2. Development of autoimmunity in MRL/lpr mice and the effects of drugs on this murine disease.
    Bartlett RR, Popovic S, Raiss RX.
    Scand J Rheumatol Suppl; 1988 Dec; 75():290-9. PubMed ID: 3238364
    [Abstract] [Full Text] [Related]

  • 3. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity--I. Disease modifying action on adjuvant arthritis of the rat.
    Bartlett RR, Schleyerbach R.
    Int J Immunopharmacol; 1985 Dec; 7(1):7-18. PubMed ID: 3873420
    [Abstract] [Full Text] [Related]

  • 4. The use of the murine chronic graft vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery.
    Popovic S, Bartlett RR.
    Agents Actions; 1987 Aug; 21(3-4):284-6. PubMed ID: 3687582
    [Abstract] [Full Text] [Related]

  • 5. Leflunomide: friend or foe for systemic lupus erythematosus?
    Wu GC, Xu XD, Huang Q, Wu H.
    Rheumatol Int; 2013 Feb; 33(2):273-6. PubMed ID: 22961090
    [Abstract] [Full Text] [Related]

  • 6. Leflunomide for the treatment of systemic lupus erythematosus: comment on the article by McMurray.
    Barthel HR.
    Arthritis Rheum; 2001 Oct; 45(5):472. PubMed ID: 11642648
    [No Abstract] [Full Text] [Related]

  • 7. The beneficial effect of leflunomide on systemic lupus erythematosus: the role of Tregs repopulation?: Comment on: Leflunomide: friend or foe for systemic lupus erythematosus? Rheumatol Int 2013, 33(2):273-6.
    Shin JI.
    Rheumatol Int; 2014 Jun; 34(6):881. PubMed ID: 23765200
    [No Abstract] [Full Text] [Related]

  • 8. 15-Deoxyspergualin (15-DOS) has a curative effect on the development of SLE-like autoimmune disease in MRL/1 mice.
    Schorlemmer HU, Bartlett RR, Seiler FR.
    Agents Actions; 1991 Sep; 34(1-2):151-5. PubMed ID: 1793021
    [Abstract] [Full Text] [Related]

  • 9. [Leflunomide in systemic lupus erythematosus].
    Kessel A, Toubi E.
    Harefuah; 2002 Apr; 141(4):355-7, 409. PubMed ID: 12017890
    [Abstract] [Full Text] [Related]

  • 10. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J, Rupanagudi KV, Kulkarni OP, Darisipudi MN, Allam R, Anders HJ.
    J Immunol; 2011 Sep 15; 187(6):3413-21. PubMed ID: 21849682
    [Abstract] [Full Text] [Related]

  • 11. Analysis of changes in joint function and peripheral blood mononuclear cells in patients with systemic lupus erythematosus and intervention effects of different drugs.
    Zhou QS, Hu J, Hu H.
    Eur Rev Med Pharmacol Sci; 2017 Oct 15; 21(19):4423-4430. PubMed ID: 29077150
    [Abstract] [Full Text] [Related]

  • 12. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus.
    Tam LS, Li EK, Wong CK, Lam CW, Szeto CC.
    Lupus; 2004 Oct 15; 13(8):601-4. PubMed ID: 15462490
    [Abstract] [Full Text] [Related]

  • 13. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection.
    Bartlett RR, Dimitrijevic M, Mattar T, Zielinski T, Germann T, Rüde E, Thoenes GH, Küchle CC, Schorlemmer HU, Bremer E.
    Agents Actions; 1991 Jan 15; 32(1-2):10-21. PubMed ID: 2058454
    [Abstract] [Full Text] [Related]

  • 14. Deoxyspergualin therapy in autoimmune MRL/1pr mice suffering advanced lupus-like disease.
    Nemoto K, Mae T, Sugawara Y, Hayashi M, Abe F, Takeuchi T.
    J Antibiot (Tokyo); 1990 Dec 15; 43(12):1590-6. PubMed ID: 2276976
    [Abstract] [Full Text] [Related]

  • 15. Interleukin-1 receptor associated kinase 1 is a potential therapeutic target of anti-inflammatory therapy for systemic lupus erythematosus.
    Li M, Yu D, Ni B, Hao F.
    Mol Immunol; 2017 Jul 15; 87():94-101. PubMed ID: 28431280
    [Abstract] [Full Text] [Related]

  • 16. [Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus].
    Wang L, Yang Y, Jia Y, Miao H, Zhou YS, Zhang XY.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec 18; 48(6):1081-1085. PubMed ID: 27987518
    [Abstract] [Full Text] [Related]

  • 17. Modulation of immunoglobulin dysregulation in graft versus host-and systemic lupus erythematosus-like diseases by malononitrilamides.
    Schorlemmer HU, Bartlett RR.
    Transplant Proc; 1998 Dec 18; 30(8):4153-5. PubMed ID: 9865331
    [No Abstract] [Full Text] [Related]

  • 18. Effects of leflunomide on experimental autoimmune myocarditis with special reference to the dendritic cells.
    Dimitrijevic M, Milenkovic M, Milosavljevic P, Colic M.
    Transplant Proc; 1998 Dec 18; 30(8):4149-50. PubMed ID: 9865329
    [No Abstract] [Full Text] [Related]

  • 19. Leflunomide for the treatment of rheumatoid arthritis and autoimmunity.
    Sanders S, Harisdangkul V.
    Am J Med Sci; 2002 Apr 18; 323(4):190-3. PubMed ID: 12003373
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.